Searched for
HERCLON
Roche launches antibody drug for breast cancer in IndiaThe drug is approved for treating both early and late stage or metastatic HER2-positive breast cancer.- Roche Pharma India expands partnership with Cipla for key oncology medicinesRoche Pharma India has signed a "distribution agreement with Cipla to expand the scope of the partnership to include, marketing and distrib...
- CCI to investigate Swiss drugmaker Roche over breast cancer biosimilarCCI’s action is in response to a complaint filed by Mylan and Biocon, who have together developed biosimilar version of Roche’s blockbuster...
- Delhi High Court gives Biocon, Mylan green light to market blockbuster biosimilar for three cancersThe court’s latest move, which allows the companies to use Roche’s product data in their package inserts, is expected to allow Biocon and M...
- Delhi HC asks government if it approved Biocon’s trastuzumab for three cancersBiosimilars are copies of complex drugs based on living cells. They are different from chemical-based generic drugs, which are 'identical' ...
- Court battle over Zydus Cadila's breast cancer drug continuesLegal experts said that the court is still in the process of hearing arguments from both sides to ascertain whether Roche could have approa...
- Court defers decision on Roche's plea against Zydus' cancer drugRoche sued Zydus Cadila and the DCGI last week, alleging that the Indian company launched its product, Vivitra, in the country without gene...
- Now, Roche takes Zydus Cadila to court over breast cancer drugThe petition states the approval of Cadila’s drug as a biosimilar has caused Roche “irreparable damage” in violation of applicable law for ...
- Roche, Biocon clash accusing contempt of courtRoche did not comment on the development, stating that the matter was sub judice. Biocon did not respond to ET's queries.
- Government set to release revised biosimilar guidelines in July 2016The ministry expects the final guidelines to uphold the safety and efficacy of biosimilar drugs hitting the Indian market through stringent...
- Reliance Life Sciences appeals marketing restrictions on breast cancer drugThe counsel is appealing conditions including the restrictions placed on the labelling of TrastuRel as well as those placed on using Roche’...
- Biotech giant Roche takes NPPA to court over cap on injection priceOn May 9, the NPPA issued a notification capping the price of trastuzumab 440mg/50ml injections at Rs 55,812.29 per pack.
- Biocon, Mylan likely to appeal Delhi HC ruling on Roche's cancer drug trastuzumabThe order, which raised questions on the processes followed by the Indian drug controller in approving such drugs, could also affect the av...
- Zydus Cadila launches copy of Roche’s breast cancer drug HerceptinZydus Cadila has introduced a breast cancer drug in India that is a copy of Swiss giant Roche’s product Herceptin, which had global sales o...
- Roche launches new breast cancer drugs in IndiaRoche Products (India) Private Ltd is a wholly owned subsidiary of the Switzerland based Roche Group and has products in therapeutic areas .
- Roche plans to roll out new drugs; plans new market access strategies in India: Maturin Tchoumi, Roche IndiaIndia is a fragmented market and has its own challenges; there is a private sector and public sector. About 80% of the healthcare expenses ...
- Roche plans to step up India play, launches two new medicinesRoche said patients will be offered equated monthly instalment schemes for Perjeta and Kadcyla through financial institutions in the coming...
- Biocon, Mylan challenge ban on using Roche dataBangalore-based Biocon and US generic drugmaker Mylan have challenged Delhi High Court’s interim order which barred them from using Roche’s...
- Biocon ups generic war with nod for Roche's cancer drug cloneBiocon officials confirmed the development to ET but didn't shed light on how soon the company would be ready to bring the biosimilar to th...
- DIPP may seek information from DCGI to manufacture generic version of Roche's anti-cancer drugWorried over the exorbitant prices of the drug in the Indian market, the ministry urged the DIPP to invoke this section.
Load More
